Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer’s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study

Abstract Background Atabecestat, a potent brain-penetrable inhibitor of BACE1 activity that reduces CSF amyloid beta (Aβ), was developed for oral treatment for Alzheimer’s disease (AD). The long-term safety and effect of atabecestat on cognitive performance in participants with predementia AD in two...

Full description

Bibliographic Details

Published in:	Alzheimer’s Research & Therapy
Main Authors:	Gerald Novak, Johannes Rolf Streffer, Maarten Timmers, David Henley, H. Robert Brashear, Jennifer Bogert, Alberto Russu, Luc Janssens, Ina Tesseur, Luc Tritsmans, Luc Van Nueten, Sebastiaan Engelborghs
Format:	Article
Language:	English
Published:	BMC 2020-05-01
Subjects:	Atabecestat BACE1 inhibitor Alzheimer’s disease Predementia Amyloid Aβ
Online Access:	http://link.springer.com/article/10.1186/s13195-020-00614-5